JP2022515158A5 - - Google Patents

Info

Publication number
JP2022515158A5
JP2022515158A5 JP2021535756A JP2021535756A JP2022515158A5 JP 2022515158 A5 JP2022515158 A5 JP 2022515158A5 JP 2021535756 A JP2021535756 A JP 2021535756A JP 2021535756 A JP2021535756 A JP 2021535756A JP 2022515158 A5 JP2022515158 A5 JP 2022515158A5
Authority
JP
Japan
Prior art keywords
disorder
compound according
disorders
pain
addiction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021535756A
Other languages
English (en)
Japanese (ja)
Other versions
JP7649743B2 (ja
JP2022515158A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/068109 external-priority patent/WO2020132605A1/en
Publication of JP2022515158A publication Critical patent/JP2022515158A/ja
Publication of JP2022515158A5 publication Critical patent/JP2022515158A5/ja
Priority to JP2024195978A priority Critical patent/JP2025024045A/ja
Application granted granted Critical
Publication of JP7649743B2 publication Critical patent/JP7649743B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021535756A 2018-12-21 2019-12-20 有機化合物 Active JP7649743B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024195978A JP2025024045A (ja) 2018-12-21 2024-11-08 有機化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862783618P 2018-12-21 2018-12-21
US62/783,618 2018-12-21
PCT/US2019/068109 WO2020132605A1 (en) 2018-12-21 2019-12-20 Organic compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024195978A Division JP2025024045A (ja) 2018-12-21 2024-11-08 有機化合物

Publications (3)

Publication Number Publication Date
JP2022515158A JP2022515158A (ja) 2022-02-17
JP2022515158A5 true JP2022515158A5 (cg-RX-API-DMAC7.html) 2022-12-14
JP7649743B2 JP7649743B2 (ja) 2025-03-21

Family

ID=71101940

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021535756A Active JP7649743B2 (ja) 2018-12-21 2019-12-20 有機化合物
JP2024195978A Withdrawn JP2025024045A (ja) 2018-12-21 2024-11-08 有機化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024195978A Withdrawn JP2025024045A (ja) 2018-12-21 2024-11-08 有機化合物

Country Status (4)

Country Link
US (2) US12331052B2 (cg-RX-API-DMAC7.html)
EP (1) EP3897621A4 (cg-RX-API-DMAC7.html)
JP (2) JP7649743B2 (cg-RX-API-DMAC7.html)
WO (1) WO2020132605A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2743513C2 (ru) 2016-01-26 2021-02-19 Интра-Селлулар Терапиз, Инк. Органические соединения
JP7224333B2 (ja) 2017-07-26 2023-02-17 イントラ-セルラー・セラピーズ・インコーポレイテッド 有機化合物
SMT202600133T1 (it) 2018-03-23 2026-05-12 Intra Cellular Therapies Inc Composti organici
AU2019240226B2 (en) 2018-03-23 2024-11-28 Intra-Cellular Therapies, Inc. Organic compounds
EP3801527B1 (en) 2018-06-08 2025-02-19 Intra-Cellular Therapies, Inc. Fused gamma-carbolines for acute treatment of anxiety or depression
IL315005B2 (en) 2018-12-17 2026-04-01 Intra Cellular Therapies Inc Substituted heterocycle fused gamma-carbolines synthesis
ES3047409T3 (en) 2018-12-17 2025-12-03 Intra Cellular Therapies Inc Substituted heterocycle fused gamma-carbolines synthesis
KR20210104785A (ko) 2018-12-17 2021-08-25 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
US12331052B2 (en) 2018-12-21 2025-06-17 Intra-Cellular Therapies, Inc. Organic compounds
JP7377871B2 (ja) 2018-12-21 2023-11-10 イントラ-セルラー・セラピーズ・インコーポレイテッド 有機化合物
CN118105390A (zh) * 2019-01-23 2024-05-31 细胞内治疗公司 治疗成瘾的方法
IL286938B1 (en) * 2019-04-04 2026-05-01 Intra Cellular Therapies Inc Methods for treating neuropathic pain
KR20240089771A (ko) * 2021-10-19 2024-06-20 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
US20250320214A1 (en) * 2022-03-14 2025-10-16 Intra-Cellular Therapies, Inc. Organic compounds
KR20250123225A (ko) 2022-12-30 2025-08-14 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
CN121152625A (zh) 2023-02-17 2025-12-16 细胞内治疗公司 用于调节神经系统的卢美哌隆和其衍生物
CN119930620A (zh) * 2024-02-05 2025-05-06 和径医药科技(上海)有限公司 四并环类化合物、其制备方法、药物组合物及应用
WO2025257090A1 (en) 2024-06-10 2025-12-18 Interquim, S.A. Process for the preparation of synthesis intermediates of lumateperone and lumateperone analogues
WO2026011136A1 (en) 2024-07-03 2026-01-08 Intra-Cellular Therapies, Inc. Organic compounds
WO2026011166A1 (en) 2024-07-03 2026-01-08 Intra-Cellular Therapies, Inc. Substituted heterocycles for use in the treatment of diseases involving the 5-ht2a receptor

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2490813A (en) 1944-11-29 1949-12-13 Standard Oil Co Continuous process for making aryl amines
US3299078A (en) 1962-10-01 1967-01-17 Smith Kline French Lab Pyrido [3', 4': 4, 5] pyrrolo [3, 2, 1-hi] indoles and-[3, 2, 1-ij] quinolines
US3813392A (en) 1969-06-09 1974-05-28 J Sellstedt Pyrrolo(1,2,3-alpha epsilon)quinoxalin-2(3h)-ones and related compounds
US4238607A (en) 1972-06-19 1980-12-09 Endo Laboratories Inc. Pyridopyrrolo benzheterocycles
US4001263A (en) 1974-04-01 1977-01-04 Pfizer Inc. 5-Aryl-1,2,3,4-tetrahydro-γ-carbolines
HU208484B (en) 1988-08-17 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
US5114976A (en) 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US6407092B1 (en) 1999-04-23 2002-06-18 Pharmacia & Upjohn Company Tetracyclic azepinoindole compounds
US7071186B2 (en) 1999-06-15 2006-07-04 Bristol-Myers Squibb Pharma Co. Substituted heterocycle fused gamma-carbolines
WO2000077001A1 (en) 1999-06-15 2000-12-21 Du Pont Pharmaceuticals Company Substituted heterocycle fused gamma-carbolines
US6713471B1 (en) 1999-06-15 2004-03-30 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
US6849619B2 (en) 2000-12-20 2005-02-01 Bristol-Myers Squibb Company Substituted pyridoindoles as serotonin agonists and antagonists
RU2003121304A (ru) * 2000-12-20 2005-01-27 Бристол-Маерс Сквибб Компани (Us) Замещенные пиридоиндолы в качестве агонистов и антагонистов серотонина
US20050222209A1 (en) 2004-04-01 2005-10-06 Zeldis Jerome B Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
US7592454B2 (en) 2004-04-14 2009-09-22 Bristol-Myers Squibb Company Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists
WO2006034187A2 (en) 2004-09-20 2006-03-30 Mount Sinai School Of Medicine Use of memantine (namenda) to treat autism, compulsivity, and impulsivity
RU2401257C2 (ru) 2004-12-07 2010-10-10 Янссен Фармацевтика Н.В. Новые замещенные тетрациклические производные тетрагидрофурана, пирролидина и тетрагидротиофена
WO2008030651A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
MX394214B (es) 2007-03-12 2025-03-24 Intra Cellular Therapies Inc Sintesis de gamma-carbolinas fusionadas con heterociclo substituido.
CN101983058A (zh) 2008-02-05 2011-03-02 克莱拉有限公司 缓解抑郁症或改善认知的组合物和方法
ES2530090T3 (es) 2008-03-12 2015-02-26 Intra-Cellular Therapies, Inc. Sólido de gamma-carbolinas fusionadas con heterociclo sustituido
CA2725342C (en) 2008-05-27 2024-02-20 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines for sleep disorders and other disorders
US8993572B2 (en) 2010-04-22 2015-03-31 Intra-Cellular Therapies, Inc. Pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines derivatives and [1,4]oxazino[2,3,4-hi]pyrido[4,3-b]indole derivatives
TWI582092B (zh) 2010-07-28 2017-05-11 歌林達股份有限公司 順式-四氫-螺旋(環己烷-1,1’-吡啶[3,4-b]吲哚)-4-胺-衍生物
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
JP5773781B2 (ja) * 2011-06-30 2015-09-02 株式会社東芝 超音波診断装置、画像処理装置及びプログラム
AU2012295810B2 (en) 2011-08-16 2016-05-26 Tosho, Inc. Tablet splitting apparatus
US9428506B2 (en) 2012-04-14 2016-08-30 Intra-Cellular Therapies, Inc. Substituted pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines for the treatment of nervous system disorders
BR112015005743A2 (pt) 2012-09-14 2017-07-04 Abbvie Deutschland derivados tricíclicos de quinoxalina e quinolina
WO2014145192A1 (en) 2013-03-15 2014-09-18 Intra-Cellular Therapies, Inc. Organic compounds
KR102967223B1 (ko) 2013-12-03 2026-05-19 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
US9745300B2 (en) 2014-04-04 2017-08-29 Intra-Cellular Therapies, Inc. Organic compounds
KR20220054908A (ko) 2014-04-04 2022-05-03 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
EP3302442B1 (en) 2015-06-03 2024-10-16 Triastek, Inc. Dosage forms and use thereof
WO2017117514A1 (en) 2015-12-31 2017-07-06 Tung Roger D Deuterated iti-007
RU2743513C2 (ru) 2016-01-26 2021-02-19 Интра-Селлулар Терапиз, Инк. Органические соединения
IL281050B2 (en) 2016-03-25 2023-04-01 Intra Cellular Therapies Inc A controlled or delayed release pharmaceutical preparation containing a deuterated compound
US20200392135A1 (en) 2016-03-25 2020-12-17 Intra-Cellular Therapies, Inc. Organic compounds
WO2017172811A1 (en) 2016-03-28 2017-10-05 Intra-Cellular Therapies, Inc. Novel co-crystals
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
WO2017172784A1 (en) 2016-03-28 2017-10-05 Intra-Cellular Therapies, Inc. Novel salts and crystals
HUE057055T2 (hu) 2016-08-09 2022-04-28 Teva Pharmaceuticals Int Gmbh Lumateperon-ditozilátsó szilárd halmazállapotú formái
JP7013454B2 (ja) 2016-10-12 2022-02-15 イントラ-セルラー・セラピーズ・インコーポレイテッド アモルファス固体分散体
EP3562484B1 (en) * 2016-12-29 2021-08-25 Intra-Cellular Therapies, Inc. Pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline derivatives useful in the treatment of cns disorders
WO2018126140A1 (en) * 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
EP3600325A4 (en) 2017-03-24 2021-01-06 Intra-Cellular Therapies, Inc. UNIQUE COMPOSITIONS AND PROCESSES
WO2018189646A1 (en) 2017-04-10 2018-10-18 Dr. Reddy's Laboratories Limited AMORPHOUS FORM AND SOLID DISPERSIONS OF LUMATEPERONE p-TOSYLATE
WO2019023062A1 (en) 2017-07-26 2019-01-31 Intra-Cellular Therapies, Inc. ORGANIC COMPOUNDS
JP7224333B2 (ja) 2017-07-26 2023-02-17 イントラ-セルラー・セラピーズ・インコーポレイテッド 有機化合物
WO2019067591A1 (en) 2017-09-26 2019-04-04 Intra-Cellular Therapies, Inc. NEW SALTS AND CRYSTALS
JP7401442B2 (ja) 2018-01-31 2023-12-19 イントラ-セルラー・セラピーズ・インコーポレイテッド 新規使用
WO2019178484A1 (en) 2018-03-16 2019-09-19 Intra-Cellular Therapies, Inc. Novel methods
SMT202600133T1 (it) 2018-03-23 2026-05-12 Intra Cellular Therapies Inc Composti organici
AU2019240226B2 (en) 2018-03-23 2024-11-28 Intra-Cellular Therapies, Inc. Organic compounds
EP3801527B1 (en) 2018-06-08 2025-02-19 Intra-Cellular Therapies, Inc. Fused gamma-carbolines for acute treatment of anxiety or depression
RS67906B1 (sr) 2018-06-11 2026-04-30 Intra Cellular Therapies Inc Sinteza supstituisanih heterociklično fuzionisanih gama-karbolina
US20220160704A2 (en) 2018-08-08 2022-05-26 Torralva Medical Therapeutics Llc Compositions for opiate and opioid prevention and reversal, and methods of their use
US12144808B2 (en) 2018-08-29 2024-11-19 Intra-Cellular Therapies, Inc. Compositions and methods
AU2019328528B2 (en) 2018-08-31 2025-01-23 Intra-Cellular Therapies, Inc. Novel methods
WO2020047408A1 (en) 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Novel methods
KR20210104785A (ko) 2018-12-17 2021-08-25 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
US12331052B2 (en) 2018-12-21 2025-06-17 Intra-Cellular Therapies, Inc. Organic compounds
JP7377871B2 (ja) * 2018-12-21 2023-11-10 イントラ-セルラー・セラピーズ・インコーポレイテッド 有機化合物
CN118105390A (zh) 2019-01-23 2024-05-31 细胞内治疗公司 治疗成瘾的方法
IL286938B1 (en) 2019-04-04 2026-05-01 Intra Cellular Therapies Inc Methods for treating neuropathic pain
WO2020223894A1 (en) 2019-05-07 2020-11-12 Nirsum Laboratories, Inc. Opioid receptor antagonist prodrugs
EP4134101A1 (en) 2019-07-07 2023-02-15 Intra-Cellular Therapies, Inc. Deuterated lumateperone for the treatment of the bipolar ii disorder
IL308750A (en) 2021-06-07 2024-01-01 Intra Cellular Therapies Inc Novel salts and crystals
KR20240089771A (ko) 2021-10-19 2024-06-20 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법

Similar Documents

Publication Publication Date Title
US8017631B2 (en) Oxadiazole derivatives and their medical use
RU2018130727A (ru) Органические соединения
JP2021519267A5 (cg-RX-API-DMAC7.html)
JP6505023B2 (ja) Cnsおよび他の障害を治療するための、pde4アイソザイムの阻害薬としてのアザベンゾイミダゾール化合物
TWI224102B (en) Serotonergic agents
TWI629276B (zh) 咪唑并嗒化合物
JP2020528430A5 (cg-RX-API-DMAC7.html)
JP2008540637A5 (cg-RX-API-DMAC7.html)
RU2016110483A (ru) Производные пирролопиридина или пиразолопиридина
RU2016140266A (ru) Спироциклические аминовые производные в качестве модуляторов s1p
WO2010026134A1 (en) Triazole derivatives and their use as nicotinic acetylcholine receptor modulators
JP2009538910A5 (cg-RX-API-DMAC7.html)
RU2008110911A (ru) Новые диазабициклические арильные производные и их медицинское применение
CN108884093B (zh) 一种多巴胺d3配体化合物
JP2007520539A5 (cg-RX-API-DMAC7.html)
JP2021529813A (ja) チアジアジン誘導体
RU2015148927A (ru) Производные изохинолина, стимулирующие нейрогенез
JP2006503062A5 (cg-RX-API-DMAC7.html)
CN102015697B (zh) 酰胺衍生物以及含有该酰胺衍生物的药物组合物
JP2011500728A (ja) 疾患の処置に有用なニコチン性アセチルコリン受容体の(1,4−ジアザ−ビシクロ[3.2.2]ノン−6−エン−4−イル)−ヘテロシクリル−メタノンリガンド
CN100534983C (zh) 环胺衍生物、其制备方法以及包含该化合物的药物组合物
CN115427409B (zh) 作为trpv4拮抗剂的嘧啶-4(3h)-酮衍生物
JP2012509860A5 (cg-RX-API-DMAC7.html)
JP2007523207A5 (cg-RX-API-DMAC7.html)
JP2006519251A5 (cg-RX-API-DMAC7.html)